Nucl Med Mol Imaging.
2022 Apr;56(2):105-109. 10.1007/s13139-022-00736-8.
Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [ 18 F]-FES PET/CT: a Case Report
- Affiliations
-
- 1Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
- 2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- KMID: 2528455
- DOI: http://doi.org/10.1007/s13139-022-00736-8
Abstract
- Accurate determination of the hormone receptor status in patients with breast cancer is necessary to provide better palliative treatment because of the frequent discordant status of hormone receptors between primary breast cancer and metastatic lesions. In particular, the invasive nature and small number of cells recovered from the cerebrospinal fluid collected through lumbar puncture limit the detailed immunocytochemistry investigation of leptomeningeal metastasis. Moreover, none of the conventional imaging modalities provide any information on the hormone receptor status of leptomeningeal metastasis in patients with breast cancer. Herein, we report estrogen receptor–positive leptomeningeal metastasis clearly demonstrated by 16α-[ 18 F]-fluoro-17β-estradiol ([ 18 F]-FES) positron emission tomography/computed tomography (PET/CT) in a patient with metastatic breast cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- New Trend of tumor PET imaging radiopharmaceuticals
- Skeletal Muscle Metastases from Breast Cancer: Two Case Reports
- Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: a Systematic Review and Meta-analysis
- Breast Cancer with Leptomeningeal Metastasis
- The Metastatic Rate of Internal Mammary Lymph Nodes When Metastasis of Internal Mammary Lymph Node Is Suspected on PET/CT
